Ratings Catalent, Inc.

Equities

CTLT

US1488061029

Market Closed - Nyse Other stock markets 04:00:02 2024-04-24 pm EDT			5-day change	1st Jan Change
55.95 ^USD	-0.14%		-0.02%	+24.53%

Apr. 12	Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48	MT
Apr. 08	Sector Update: Health Care Stocks Decline Late Afternoon	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's enterprise value to sales, at 3.38 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
CATALENT, INC.	+24.53%	10.14B	C
ELI LILLY AND COMPANY	+25.61%	672B	C+
NOVO NORDISK A/S	+25.87%	570B	B
JOHNSON & JOHNSON	-5.24%	360B	C+
MERCK & CO., INC.	+16.49%	321B	B-
ABBVIE INC.	+8.28%	300B	C+
ASTRAZENECA PLC	+7.09%	217B	B+
ROCHE HOLDING AG	-9.12%	204B	A+
NOVARTIS AG	+5.01%	199B	B-
PFIZER, INC.	-8.75%	149B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes